Consultant, Clinical Pharmacology
Esperion Therapeutics, Inc.
Maurice (Maury) Emery, PharmD, PhD, is currentrly an independent contractor/principal at Akamai Clin Pharm Consulting, Inc. Maury received his BS Pharm and PharmD degrees from the University of Minnesota. Following graduation, he joined the University of Utah faculty in Pharmacy Practice for 10 years where he attained the rank of Associate Professor. After a 3-year position in the post-marketing medical department at Bristol-Myers, he returned to the University of Washington to complete a PhD degree in Pharmaceutics. Following his completion of the PhD program, he joined Abbott Laboratories for 4 years, then spent 12 years at Amgen as a clinical pharmacologist the for an anti-PCSK9 monoclonal antibody (Repatha), approved in 2014. He then moved to the Seattle Genetics as the head of the Clinical Pharmacology group working on antibody-drug conjugates. After a very short retirement, he joined Esperion Therapeutics as a clinical pharmacologist completing the NDA and MAA filings for a novel lipid lowering therapy (Nexletol) and a fixed-dose combination with ezetimibe (Nexlizet), approved in early 2020 by the FDA and EMA. Maury has experience across all stages of drug development in the areas of oncology, inflammation, metabolic and cardiovascular therapeutics. He has been a member of ASCPT for 16 years, serving on many committees and on the Board of Directors. He has authored over 50 peer reviewed publications and 4 book chapters. He and his wife, Tami Pu'u, live on the slopes of Haleakala in Upcountry Maui, Hawai’i. They have 4 daughters, 3 Nigerian dwarf dairy goats and 2 kittens. He enjoys a small amount of farming in addition to driving (and occasionally working on their 2 British (MG) roadsters.